The University of Edinburgh is to lead a £4.75 million UK government project to sequence the genomes of 6,000 people with ME/CFS — what the government describes as a world-first genomics study of a condition that affects around 390,000 people in the UK and which to date has no diagnostic test and no licensed treatment.
The University of Edinburgh is to lead a £4.75 million UK government project to sequence the complete genomes of 6,000 people with myalgic encephalomyelitis, also known as chronic fatigue syndrome — described by the government as a world-first genomics study of the condition. The programme, called SequenceME, will draw its participants from the DecodeME cohort, the world’s largest existing ME/CFS research cohort.
The funding comes from the Department of Health and Social Care, channelled through the National Institute for Health and Care Research and the Medical Research Council. The work will be hosted at the University of Edinburgh’s Institute of Genetics and Cancer, with project partners including the charity Action for ME, the European Molecular Biology Laboratory’s European Bioinformatics Institute, and sequencing technology provider Oxford Nanopore Technologies.
The SequenceME phase forms part of a planned £20 million international effort that ultimately aims to analyse the genomes of 9,000 people with ME/CFS and 9,000 people with Long Covid, according to the University of Edinburgh. The technology choice matters: Oxford Nanopore’s long-read whole-genome sequencing can resolve rare structural genetic variants that shorter-read methods routinely miss, allowing the team to look for the kind of variation that broader, lower-resolution surveys would not detect.
ME/CFS affects around 390,000 people in the UK, according to the UK government, with around a quarter of those diagnosed severely affected — leaving them housebound or unable to work. There is no diagnostic test and no licensed treatment.
Professor Chris Ponting, DecodeME investigator at the University of Edinburgh, said: “By deeply sequencing the complete genomes of 6,000 DecodeME participants using advanced long-read technology, this project will allow us to pinpoint individual genes disrupted in ME/CFS, moving beyond broader chromosomal signals identified to date. Crucially, it offers the potential to uncover patterns of familial inheritance and to break down this complex disease into its underlying biological causes — bringing us closer to more precise diagnosis and, ultimately, targeted treatments.”
Sonya Chowdhury, Chief Executive of Action for ME, said: “We are delighted to receive this investment in SequenceME and long COVID to enable us to start sequencing DNA samples. This project builds on DecodeME and creates even greater value from the samples provided by people with ME/CFS.
“However, there is more to do, and this must be only a start to the significant investment in ME/CFS research that is so desperately needed to bring funding to the levels seen in other illness areas. ME/CFS research has been neglected for decades; research in ME/CFS and overlapping illnesses like long COVID must become a priority. We are very grateful not only to DHSC but also to our charity partners and donors who have helped make this possible.”
The patient response to the announcement has been notable for the diagnostic-journey context it surfaces. Aisling Baker-Ford, 32, from Ayrshire, who was diagnosed with ME in 2022, told the government in its announcement: “I was diagnosed with ME in 2022 after a 2 and a half year battle with a range of specialists — even a neurologist telling me ‘it is all in my head’. This unfortunately is a very common occurrence for people like me with this condition.
“I hope this funding allows further understanding and to identify significant genetic links of this condition. I hope [for] more awareness of ME and how it can affect someone’s life from all levels of the condition and not just the worst, most severe cases.”
Dr Charles Shepherd, Honorary Medical Adviser to the ME Association, said: “The ME Association is delighted by the government decision to invest £4.75 million in new research funding to allow vital research into the role of genetics in ME/CFS to continue.
“Building on the findings from DecodeME, SequenceME should provide a better understanding of the underlying disease process, in particular how the immune and nervous systems respond to a triggering infection in ME/CFS.
“For people with ME/CFS there is now real hope that we have a route to finding a much-needed diagnostic biomarker blood test and effective forms of treatment.”
For Edinburgh, the project consolidates a position as a UK and European centre for population-scale genomics in contested or under-researched diseases, alongside existing programmes in psychiatric and rare disease genetics. The choice of Oxford Nanopore as the sequencing partner also strengthens ties between Edinburgh’s clinical genomics base and a UK long-read sequencing industry that competes globally with US incumbents.
The University of Edinburgh has confirmed that patients and carers will help shape SequenceME’s priorities and study design — a governance feature unusual for a programme of this scale and consistent with the patient-led history of DecodeME.